NCT03067727 - A Randomised Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

August 30, 2018

Study Completion Date

August 30, 2018

Conditions

Cervical Ripening

Interventions

DRUG

Dinoprostone

The DVI contains 10 mg Dinoprostone

DRUG

Placebo

The placebo product is identical with the active product except that it does not contain Dinoprostone.

Trial Locations (20)

Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi

Hamamatsu University Hospital, Hamamatsu

Seirei Hamamatsu General Hospital, Hamamatsu

Jichi Medical University Hospital, Shimotsuke

Itabashi Chuo Medical Center, tabashi City

Asahi General Hospital, Chiba

University of Tsukuba Hospital, Ibaraki

Hori Hospital, Kanagawa

Aizenbashi Hospital, Osaka

Osaka University Hospital, Osaka

Rinku General Medical Center, Osaka

Juntendo University Hospital, Tokyo

Keio University Hospital, Tokyo

Seibo Hospital, Tokyo

Showa University Hospital, Tokyo

St.Luke's International Hospital, Tokyo

The University of Tokyo Hospital, Tokyo

Tokyo Metropolitan Bokutoh Hospital, Tokyo

Tokyo Metropolitan Tama Medical Center, Tokyo

Keiyu Hospital, Yokohama